London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement with Professor Chris Lord’s lab at The Institute of Cancer Research, London. The collaboration will use NeoPhore’s proprietary small molecule inhibitors of DNA mismatch repair (‘MMR’) to investigate single agent activity against tumours […]
Agreement to manufacture Leucid Lead asset, LEU011 for the treatment of solid tumours and haematological malignancies utilising facilities and quality assurance services at the Zayed Centre for Research into Rare Disease in Children is first-of-its-kind. Leucid Bio to retain IP in respect of services arising from this venture. Leucid Bio expects to file its CTA […]
Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a three-year research collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, USA. The objective of the collaboration is to determine the potential of NeoPhore’s proprietary DNA mismatch repair inhibitor (MMRi) compounds to enhance […]
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into an exclusive licensing agreement with Cooper Consumer Health (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise the […]
Deal value includes upfront payment of US$100 million with F2G eligible for additional regulatory and commercial milestones of up to US$380 million, as well as double-digit royalties on net sales and share development costs Validation of Novo Holdings’ strategy to identify and invest in promising European biotech opportunities Novo Holdings A/S, a leading international life sciences […]
